Intelligent Bio Solutions, Inc. has filed a prospectus related to the resale of 6,781,166 shares of common stock by identified selling stockholders. The shares available for resale include those acquired by certain stockholders in a private placement transaction on March 8, 2024, under a Purchase Agreement. The transaction involved 6,669,999 shares of common stock and various series of warrants that could potentially be exercised for additional shares. Additionally, 111,167 shares are issuable upon the exercise of warrants issued to the placement agent, Ladenburg Thalmann & Co. Inc., and its designees. The company will not receive any proceeds from the resale of the shares by the selling stockholders but will receive proceeds from any cash exercise of the warrants, intended for working capital and general corporate purposes...Show More

Intelligent Bio Solutions, Inc. has filed a prospectus related to the resale of 6,781,166 shares of common stock by identified selling stockholders. The shares available for resale include those acquired by certain stockholders in a private placement transaction on March 8, 2024, under a Purchase Agreement. The transaction involved 6,669,999 shares of common stock and various series of warrants that could potentially be exercised for additional shares. Additionally, 111,167 shares are issuable upon the exercise of warrants issued to the placement agent, Ladenburg Thalmann & Co. Inc., and its designees. The company will not receive any proceeds from the resale of the shares by the selling stockholders but will receive proceeds from any cash exercise of the warrants, intended for working capital and general corporate purposes. The selling stockholders may sell the shares through various methods, including ordinary brokerage transactions, block trades, or private transactions, at market prices or negotiated prices. Intelligent Bio Solutions' common stock is listed on The Nasdaq Capital Market under the symbol 'INBS'. The last reported sale price of the company's common stock was $4.45 per share as of March 27, 2024. The prospectus also includes details on the company's recent developments, including reverse stock splits in January 2024 and February 2023, and compliance with Nasdaq's continued listing requirements.